

Externally-Led Patient Focused Drug Development Meeting on

Kidney Xenotransplantation

Meeting Agenda

	November 9th, 2023 10:00am – 3:30pm ET Grand Ballroom (Salons A-C)	
8:00-10:00 AM	Breakfast provided for all registered in-person attendees	Grand Ballroom Salons D/E
10:00-10:10 AM	Welcome from the National Kidney Foundation	Kevin Longino, CEO; NKF Heather Murphy, MA, NKF
10:10-10:20 AM	Opening Remarks from the U.S. Food and Drug Administration	Patricia Beaston, MD, FDA
10:20-10:30 AM	Kidney Xenotransplantation Overview & Development Update	Vineeta Kumar, MD
10:30-10:35 AM	Introduction & Meeting Overview	James Valentine, JD, MHS, Moderator
10:35-10:45 AM	Demographic Polling	

Patient Experiences & Preferences to Inform Development of Kidney Xenotransplantation

10:45-11:20 AM	Patient & Care Partner Testimony Panel	Patient & Care Partner Panelists
Discussion A	Patient Experiences with Kidney Disease: Why Patients May Consider Kidney Xenotransplantation (Expecta	itions & Outcomes)
11:20-12:00 PM	Audience Polling & Moderated Discussion	In Person & Virtual Audiences
12:00-1:00 PM	LUNCH BREAK	Grand Ballroom Salons D/E
Discussion B	Patient Considerations of Risk & Other Downsides of Kidney Xenotransplantation: Known & Unknown Prior to First In-Human Clinical Trials	
1:00-1:10 PM	The Known and Unknown Risks of Kidney Xenotransplantation	Peter Reese, MD
1:10-2:10 PM	Audience Polling & Moderated Discussion	In Person & Virtual Audiences
Discussion C	Considerations for Participating in Kidney Xenotransplantation Clinical Trials	
2:10-2:15 PM	Discussion Prompt: Considerations for Phase 1 Clinical Trial	James Valentine, JD, MHS, Moderator
2:15-3:10 PM	Audience Polling, Discussion Panel & Moderated Discussion	Patient & Care Partner Panelists; In Person & Virtual Audiences
3:10-3:20 PM	Summary Remarks	David Feldman, PhD, NKF
3:20-3:30 PM	Closing Remarks & Adjourn	Heather Murphy, MA, NKF

National Kidney Foundation 2023 | Thank you to our meeting sponsors:





